Genetic polymorphisms and drug interactions leading to clopidogrel resistance: Why the asian population requires special attention

International Journal of Neuroscience

Volumn 123, Issue 3, 2013, Pages 143-154

  Hasan, Md Shariful ^a   Basri, Hamidon Bin ^a   Hin, Lim Poh ^a   Stanslas, Johnson ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Asian; Clopidogrel resistance; Interindividual variability; Pharmacogenomics

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450; ERYTHROMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; NEFAZODONE; OMEPRAZOLE; PHENPROCOUMON; PRAVASTATIN; PURINERGIC P2Y12 RECEPTOR;

ANTICOAGULANT THERAPY; ARTICLE; ASIAN; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; HUMAN; ISCHEMIC HEART DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRESCRIPTION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84873909989     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.744308     Document Type: Article

References (98)

1. Gerald F. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clin Res ed.). 2002;324:71-86.
2. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45: 1157-64.
3. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.
4. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res. 2007;120:311-21.
5. Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F. High on treatment platelet reactivity. Heart Lung Circ. 2012;21:12-21.
6. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drugeluting stent implantation. Eur Heart J. 2008;29:992-1000.
7. Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, Tantry US. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets. 2008;19:595-604.
8. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilatorstimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630-6.
9. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Scḧomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drugeluting stent thrombosis. J Am Coll Cardiol. 2009;53:849-56.
10. Xie H-G, Zou J-J, Hu Z-Y, Zhang J-J, Ye F, Chen S-L. Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. Pharmacol Ther. 2011;129:267-89.
11. Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost. 2007;98:707-9.
12. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon M-C, Hurbin F, Sultan E. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost. 2011;105:696-705.
13. Huber K. Genetic variability in response to clopidogrel therapy: clinical implications. Eur Heart J. 2010;31:2974-6.
14. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Scḧomig A, Scḧomig E. Impact of Pglycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501.
15. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Ḿeneveau N, Steg PG, Ferrìeres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-75.
16. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320-8.
17. Harmsze AM, vanWerkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AWJ, Ruven HJT, Hackeng CM, Klungel OH, de Boer A, Deneer VHM. CYP2C19?2 and CYP2C9?3 alleles are associated with stent thrombosis: a casecontrol study. Eur Heart J. 2010;31:3046-53.
18. FDAUS SafetyCommunication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm203888.htm
19. Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56:321-41.
20. Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-58.
21. Momary KM, Dorsch MP, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy. 2010;30:265-74.
22. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT,Walker JR, Antman EM,MaciasW, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
23. Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot J-S, Kastrati A,Montalescot G, Neumann F-J, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-30.
24. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J-S, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328-32.
25. Holmes DR Jr., Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. Circulation. 2010;122:537-57.
26. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J, Johnson JA. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328-32.
27. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med. 2011;78:243-57.
28. Bauer T, Bouman HJJ, vanWerkum JWW, Ford NFF, ten Berg JMM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
29. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and metaanalysis. JAMA. 2011;306:2704-14.
30. Mega JL, Topol EJ, SabatineMS. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307:1482-5.
31. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-57.
32. Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128:307-16.
33. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-71.
34. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-36.
35. Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH. Besides CYP2C19?2, the variant allele CYP2C9?3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics. 2010;20:18-25.
36. Bouman HJ, Scḧomig E, van Werkum JW, Velder J, Hackeng CM, Hirschḧauser C, Waldmann C, Schmalz H-G, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-6.
37. Lewis JP, Fisch AS, Ryan K, O'Connell JR, Gibson Q,Mitchell BD, Shen H, Tanner K, Horenstein RB, Pakzy R, Tantry US, Bliden KP, Gurbel PA, Shuldiner AR. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther. 2011;90:568-74.
38. Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann F-J. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circulation. Cardiovasc Genet. 2011; 4:429-36.
39. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Scḧomig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32:1605-13.
40. Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, SugiyamaD,DegorterMK,Woolsey S, Tirona RG, Kim RB. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J. 2012. [Epub ahead of print]. doi: 10.1093/eurheartj/ehs042.
41. Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2009;133:341-5.
42. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Raḿ?rez C, Barrera-Ramirez C, Sabat́e M, Herńandez R, Moreno R, Escaned J, Alfonso F, Bã nuelos C,Costa MA, Bass TA, Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005;115:101-8.
43. Bonello L, Bonello-Palot N, Armero S, Bonello C, Mokhtar OA, Arques S, Dignat-George F, Camoin-Jau L, Paganelli F. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res. 2010;125:e167-70.
44. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;174:1715-22.
45. Lau WC,Waskell LA,Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2002;107:32-7.
46. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483-94.
47. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 52:1557-63.
48. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrelmediated platelet inhibition. Heart (British Cardiac Society). 2010; 96:186-9.
49. Bates ER, Lau WC, Angiolillo DJ: Clopidogrel-drug interactions. J Am Coll Cardiol. 2011; 57:1251-63.
50. Sibbing D, Beckerath NVV, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Scho A, Kastrati A, von Beckerath N, Scḧomig A. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J. 2010;31:1205-11.
51. Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007;120:188-92.
52. Siller-Matula JM, Delle-Karth G. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding. Evid Based Med. 2011;16:144-5.
53. Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall J-F, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-60.
54. Mistry SD, Trivedi HR, Parmar DM, Dalvi PS, Jiyo C. Impact of proton pump inhibitors on efficacy of clopidogrel: review of evidence. Indian J Pharmacol. 2011;43:183-6.
55. Kwan J, Htun WW, Huang Y, KoW, Kwan TW. Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention. Vasc Health and Risk Manag. 2011;7:399-404.
56. Tran M, Tafreshi J, Pai RG. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. JCardiovasc Pharmacol Ther. 2010;15:326-37.
57. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006;3:387-95.
58. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-34.
59. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-5.
60. Guha S, Mookerjee S, Guha P, Sardar P, Deb S, Roy PD, Karmakar R, Mani S, Hema MB, Pyne S, Chakraborti P, Deb PK, Lahiri P, Chaudhuri U. Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management. Indian Heart J. 2009;61: 348-52.
61. AradiD,Koḿ ocsi A. Platelet function monitoring in patients on clopidogrel: what should we learn from GRAVITAS? Platelets. 2012;23:167-76.
62. Geisler T, LangerH,Wydymus M, G̈ohring K, Z̈ urn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-5.
63. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, PencinaMJ, Scirica BM, Longtine JA,Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306:2221-8.
64. Trenk D, Hochholzer W, Fromm MF, Chialda L-E, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn H-P, B̈ uttner HJ, Neumann F-J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-34.
65. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD,Makuc DM, Marcus GM,Marelli A, Matchar DB, McDermott MM, Meigs JB,Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
66. Ong TZ, Raymond AA. Risk factors for stroke and predictors of one-month mortality. Singapore Med J. 2002;43:517-21.
67. Delcourt C, HackettM,Wu Y, Huang Y,Wang J,Wong L, Sun J, Li Q,Wei JW, Liu M, Li Z, Cheng Y,Huang Q, Xu E, Yang Q, Lu C, Craig S. Determinants of quality of life after stroke in China: the China QUEST (QUality Evaluation of Stroke care and Treatment) study. Stroke. 2011;42:433-8.
68. Venketasubramanian N, Tan LCS, Sahadevan S, Chin JJ, Krishnamoorthy ES, Hong CY, Saw SM. Prevalence of stroke among Chinese, Malay, and Indian Singaporeans: a community-based tri-racial cross-sectional survey. Stroke. 2005;36:551-6.
69. Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess (Winchester, England). 2011;15:1-178.
70. Luk HH, Pang J, Li LSW, Ng M. Use of antiplatelet drugs in the stroke unit of a Hong Kong hospital. Pharm World Sci. 2005;27:258-62.
71. Uchiyama S, Fukuuchi Y, Yamaguchi T. The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two phase III, multicenter, randomized clinical trials. J Neurol. 2009;256:888-97.
72. Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS. Association of cytochrome P450 2C19?2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drugeluting stents. Heart. 2011;98:139-44.
73. Kim KA, Park PW, Hong SJ, Park J-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-42.
74. Lee JM, Park S, Shin D-J, Choi D, Shim CY, Ko Y-G, Kim JS, Shin E-S, Chang CW, Lee J-E, Jang Y. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol. 2009;104:46-51.
75. Kim I-S, Jeong Y-H, Park Y, Park K-S, Yun S-E, Park J-R, Hwang S-J, Koh E-H, Kwak CH, Hwang J-Y, Kim S. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv. 2011;4:381-91.
76. Park KJ, Chung HS, Kim SR, Kim HJ, Han JY, Lee SY. Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med. 2011;31:91-4.
77. Park KW, Kang J, Park JJ, Yang H-M, Lee H-Y, Kang H-J, Koo B-K, Oh B-H, Park Y-B, Kim H-S. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart (British Cardiac Society). 2012;98: e1366-72.
78. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E,KawatoM, Ikeda T, YamamotoH, AkaoM, Furukawa Y, Shizuta S,Toma M, Tamura T, Saito N, Doi T, Ozasa N, Jinnai T, Takahashi K, Watanabe H, Yoshikawa Y, Nishimoto N, Ouchi C, Morimoto T, Kita T, Kimura T. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J. 2009;73:336-42.
79. Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an activemetabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008;6:1439-41.
80. Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida a, Kobayashi T, Hosohata K, Ushijima K, Fujimura A. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther. 2011;89:229-33.
81. Kumar S, Saran RK, Puri A, Gupta N, Sethi R, Surin WR, Dikshit M, Dwivedi SK, Narain VS, Puri VK. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. Indian Heart J. 2007;59:152-6.
82. Guha S, Sardar P, Guha P, Roy S, Mookerjee S, Chakrabarti P, Deb PK, Chaudhuri U, Deb S, Karmakar R, Dasgupta AK, Lahiri P. Dual antiplatelet drug resistance in patients with acute coronary syndrome. Indian Heart J. 2009;61:68-73.
83. Wang L, Wang X, Chen F. Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs in R & D. 2010;10:219-24.
84. Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, Chen JW. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105:1705-9.
85. Luo Y, Zhao YT, Verdo A, Qi WG, Zhang DF, Hu B. Relationship between cytochrome P450 2C19?2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res. 2011;39:2012-9.
86. Cave W, Pandey P, Chatterjee S. Irrational prescribing in South Asia: a case of fluoroquinolone-associated phototoxicity. J Travel Med. 2003;10:290-2.
87. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Am J Cardiol. 2000;36:699-705.
88. Vallurupalli NG, Goldhaber SZ. Gastrointestinal complications of dual antiplatelet therapy. Circulation. 2006;113:e655-8.
89. Seddighzadeh A, Wolf AT, Parasuraman S, Shetty R, Vallurupalli N, Reddy S, Goldhaber SZ. Gastrointestinal complications after 3 months of dual antiplatelet therapy for drug-eluting stents as assessed by wireless capsule endoscopy. Clin Appl Thromb Hemost. 2009;15:171-6.
90. Rogacka R, Chieffo A, Michev I, Airoldi F, Latib A, Cosgrave J, Montorfano M, Carlino M, Sangiorgi GM, Castelli A, Godino C, Magni V, Aranzulla TC, Romagnoli E, Colombo A.Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv. 2008;1:56-61.
91. Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep. 2011;38:1697-702.
92. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306: 1215-23.
93. Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, Shinohara M, Toh R, Ishida T, Kawamori H, Kozuki A, Inoue T, Hariki H, Hirata K. Impact of cytochrome P450 2C19?2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J. 2010;75:99-105.
94. Wang X, ZhangD, Zhuang S, Lai Y. Clinical investigationmodifying clopidogrel maintenance doses according to vasodilatorstimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol. 2011;34:332-8.
95. Aradi D, Vorobcsuk A, Koḿ ocsi A. Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account? J Am Coll Cardiol. 2008;52:1349; author reply 1349-50.
96. Cuisset T, Frere C, Quilici J, Alessi MC, Bonnet JL. Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late? J Am Coll Cardiol. 2008;52:790-1; author reply 791-2.
97. Fu Q, Suzuki N, Takada K. Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 2/2 genotype. Cardiovasc Interv Ther. 2010;26:79-82.
98. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E. Impact of Pglycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501.